Ondansetron Accord

Ondansetron, the active ingredient in Ondansetron Accord, is a 5-HT3 receptor antagonist presented as a tablet for oral use. It treats nausea and vomiting associated with chemotherapy, radiation therapy, and surgery in adult and pediatric patients. GNH USA supplies Ondansetron Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

GNH USA supplies Ondansetron Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Ondansetron Accord is a selective 5‑HT3 receptor antagonist used to prevent and treat nausea and vomiting in several clinical settings.

- Chemotherapy‑induced nausea and vomiting: helps control acute and delayed episodes in cancer patients. - Radiation‑induced nausea and vomiting: reduces the frequency and severity of symptoms during radiotherapy. - Post‑operative nausea and vomiting: decreases the incidence of nausea after surgical procedures. - Pregnancy‑related hyperemesis gravidarum: provides relief when other measures are insufficient. - Anticipatory nausea: lessens nausea that occurs before chemotherapy in patients with a history of severe CINV.

Side effects are generally mild but can vary in frequency and severity.

Common Side Effects: - Headache: mild to moderate pain often reported. - Constipation: reduced bowel movements. - Diarrhoea: loose stools. - Fatigue: feeling of tiredness. - Dizziness: light‑headed sensation. - Injection site pain (if administered parenterally).

Serious or Rare Side Effects: - Cardiac arrhythmia: QT‑interval prolongation may lead to irregular heart rhythm. - Severe allergic reaction: rash, itching, swelling, or difficulty breathing. - Serotonin syndrome: rare when combined with other serotonergic agents. - Hepatic dysfunction: elevated liver enzymes. - Vision changes: blurred vision or visual disturbances. - Severe constipation or bowel obstruction.

Before using Ondansetron Accord, consider the following safety measures:

- Cardiac monitoring: patients with known QT prolongation or electrolyte imbalance should be monitored. - Drug interactions: review concomitant medications that may affect cardiac rhythm. - Pregnancy: use only if the potential benefit outweighs risk; discuss with a healthcare provider. - Breastfeeding: assess risk versus benefit before use while nursing. - Renal or hepatic impairment: dose adjustment may be required; consult prescriber. - Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Ondansetron may interact with several medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Amiodarone: may increase risk of QT prolongation. - Certain anti‑arrhythmic drugs (e.g., sotalol, quinidine): additive effect on cardiac repolarization. - Antifungal agents (e.g., ketoconazole, itraconazole): can raise ondansetron plasma levels.

Moderate Interactions (Monitor Closely): - Selective serotonin reuptake inhibitors (SSRIs) and serotonin‑norepinephrine reuptake inhibitors (SNRIs): may increase serotonin syndrome risk. - Tramadol and other opioids: combined use may heighten serotonin‑related adverse effects. - Carbamazepine: may reduce ondansetron concentrations. - Metoclopramide: overlapping anti‑emetic mechanisms may require dose adjustment.